OmidHamidMD
Oncology • Los Angeles, CAHematologic Oncology, Melanoma, Complementary and Integrative
Chief, Reasearch & Immuno-Oncology
Dr. Hamid is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
11800 Wilshire Blvd
Fl 3
Los Angeles, CA 90025Phone+1 310-231-2121Fax+1 310-967-1744- Is this information wrong?
Education & Training
University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2004 - 2005- University of Southern California/LAC+USC Medical CenterFellowship, Hematology, 2003 - 2004
- University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2002 - 2003
- University of Southern California/LAC+USC Medical CenterResidency, Internal Medicine, 1999 - 2002
Keck School of Medicine of the University of Southern CaliforniaClass of 1999
Certifications & Licensure
CA State Medical License 2001 - 2024
Clinical Trials
- Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma Start of enrollment: 2010 Jun 22
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Start of enrollment: 2011 May 25
- A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma Start of enrollment: 2012 Jun 03
- Join now to see all
Publications & Presentations
PubMed
- Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity.Isabella C Glitza, Yongwoo David Seo, Christine N Spencer, Jennifer R Wortman, Elizabeth M Burton, Farah A Alayli, Christopher P Loo, Shikha Gautam, Ashish Damania, Ju...> ;Cancer Discovery. 2024 Apr 4
- Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy.Allison Betof Warner, Omid Hamid, Krishna Komanduri, Rodabe Amaria, Marcus O Butler, John Haanen, Sarah Nikiforow, Igor Puzanov, Amod Sarnaik, Michael R Bishop, Adam J...> ;Journal for Immunotherapy of Cancer. 2024 Feb 29
- Sunitinib in Patients With Breast Cancer WithorAmplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.Calfa, C., Rothe, M., Mangat, P., Garrett-Mayer, E., Ahn, E., Burness, M., Gogineni, K., Rohatgi, N., Al Baghdadi, T., Conlin, A., Gaba, A., Hamid, O., Krishnamurthy, ...> ;JCO Precision Oncology. 2024 Feb 1
- Join now to see all
Journal Articles
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the BrainKim Margolin, Omid Hamid, Christopher D Lao, Anna C Pavlick, Michael A Postow, F Stephen Hodi, Nikhil I Khushalani, Marc S Ernstoff, Hussein A Tawbi, Igor Puzanov, Ahm..., The New England Journal of Medicine
Other
- Mucosal melanomaHamid O, Ariyan C, Carvajal RD
http://www.uptodate.com/contents/mucosal-melanoma
UpToDate, Wolters Kluwer Health - 2012-06-11
Authored Content
- ESMO 2021: Leaving Paris Energized to Return to Patient CareSeptember 2021
Press Mentions
Fianlimab (LAG-3 Inhibitor) Combined with Libtayo® (Cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient PopulationsMay 26th, 2023- Immunocore Presents Promising Initial Phase 1 Data for First Off-the-Shelf TCR Therapy Targeting PRAME at the ESMO 2022 CongressSeptember 9th, 2022
- Libtayo® (Cemiplimab-Rwlc) Presentations at ASCO Highlight Expanding Clinical Data in Diverse CancersMay 20th, 2021
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
Providence Saint John's Health CenterSanta Monica, California
Cedars-Sinai Medical CenterLos Angeles, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
